Digest Network Come funziona
Network
/
Società
Ex
Non verificato

Exelixis, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

51 comunicati stampa

Guarda tutti i comunicati
24/02/2026
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Oncologia
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March
Fonte
Exelixis, Inc.
Emittente
Business Wire
1.00
0
10/02/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
Fonte
Exelixis, Inc.
Emittente
Business Wire
1.00
0
02/02/2026
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
Fonte
Exelixis, Inc.
Emittente
Business Wire
1.00
0
27/01/2026
Farmaceutica
Salute
Oncologia
Mercato azionario
Finanza
Web e Social Network
Telefonia e Varie
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
Fonte
Exelixis, Inc.
Emittente
Business Wire
1.00
0
11/01/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Finanza
Eventi
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Farmaceutica
Biotecnologia
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
Fonte
Exelixis, Inc.
Emittente
Business Wire
1.00
0
07/01/2026
Multimedialità
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Mercato del lavoro
Industria
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
Fonte
Exelixis, Inc.
Emittente
Business Wire
1.00
0
06/01/2026
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Oncologia
Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
Fonte
Exelixis, Inc.
Emittente
Business Wire
1.00
0
03/12/2025
Oncologia
Salute
Sanità
Scienza
Farmaceutica
Biotecnologia
Web e Social Network
Eventi
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
Fonte
Exelixis, Inc.
Emittente
Business Wire
1.00
0
06/11/2025
Biotecnologia
Salute
Oncologia
Eventi
Web e Social Network
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
Fonte
Exelixis, Inc.
Emittente
Business Wire
1.00
0
04/11/2025
Biotecnologia
Farmaceutica
Salute
Oncologia
Web e Social Network
Telefonia e Varie
Mercato azionario
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Fonte
Exelixis, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0